CALA News and Press, Calithera Biosciences Inc. From 07/13/22

Gainers: Theravance Biopharma ( TBPH ) +26% . Innoviva ( INVA ) +11% . Calithera Biosciences ( CALA ) +7% . Swvl Holdings ( SWVL ) +5% . Microsoft Corporation ( MSFT ) +5% . Losers: Azenta ( AZTA ) -11% . BELL...

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telagle...

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, toda...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We just saw a spate of stock-spit announcements, including from high-profile companies, such as Amazon (NASDAQ: AMZN ). While a stock split may be all too familiar for you, a reverse split is not a very common corpora...

Gainers: Calithera Biosciences (CALA) +4%. Allakos (ALLK) +3%. CorMedix (CRMD) +2%. Core Scientific (CORZ) +2%. Greenidge Generation Holdings (GREE) +2%. Losers: CalAmp (CAMP) -15%. LendingTree (TREE) -14%. The RealReal (REAL) -8%. Ikena Oncology (IKNA) -6%. Rain Therapeutics (RAIN)...

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or CD79b mutations SOUTH SAN FRANCISCO, Calif., J...

Calithera Biosciences (NASDAQ:CALA) announced that it has filed to effect a 1-for-20 reverse stock split, effective today after market close. The reverse stock split was effected by Calithera in accordance with the authorization, and within the split ratio range, adopted by Calithera stockhol...

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporati...

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will pr...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off the final day of the workweek with an overview of the biggest pre-market stock movers for Friday! Source: f11photo/Shutterstock.com A statement from Elon Musk, several earnings reports, and...